BSV-002

Influenza A

PreclinicalActive

Key Facts

Indication

Influenza A

Phase

Preclinical

Status

Active

Company

Kimer Med builds modular, host‑targeted biologics to deliver broad‑spectrum antivirals for pandemic‑ready therapeutics.

Drug	Company	Phase	Status
CC-42344 (Oral PB2 inhibitor)	Cocrystal Pharma	Phase 2	Phase 2a human challenge study complete.
CC-42344 (Inhaled PB2 inhibitor)	Cocrystal Pharma	Phase 1	Phase 1 complete; GLP tox study complete. Preparations underway for clinical testing.